Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,500 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05776407 | Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 12 | Chongqing University Cancer HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05776940 | Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis | unknown | Phase 3 | 116 | Air Force Military Medical University, ChinaOTHER | 0 | Mar 20, 2023 |
| clinicaltrials |
| NCT02931942 | Changing Over Time of Ascorbic Acid After Chemotherapy | unknown | — | 150 | Maastricht University Medical CenterOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04674514 | APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 48 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05755828 | Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma | unknown | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04941937 | Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM | unknown | Phase 2 | 90 | Juan DuOTHER | 1 | Feb 27, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05744037 | Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells | unknown | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05739188 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05740891 | AHSCT Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Multiple Myeloma | unknown | Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05712083 | A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma | unknown | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04309084 | Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | unknown | Phase 1 | 29 | Celularity IncorporatedINDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03797170 | Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma | unknown | — | 50 | University of BolognaOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718401 | The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics | unknown | — | 500 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04381741 | CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma(CICPD) | unknown | Phase 1 | 24 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04706936 | Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04887025 | Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma | unknown | Phase 1 | 25 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05210907 | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia | unknown | Phase 1 | 5 | Seoul National University HospitalOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05585996 | Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma | unknown | Phase 1 | 70 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05667155 | Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma | unknown | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | unknown | Phase 2 | 46 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Feb 3, 2023 | clinicaltrials |
| NCT05432414 | PVd Versus Vd in NDMM Patients With RI | unknown | Phase 2 | 79 | RenJi HospitalOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05698303 | A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 12 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03252600 | Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | unknown | Phase 2 | 53 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05693012 | Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple Myeloma | unknown | — | 398 | Qiu LuguiOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05690191 | Chidamide in Patients With Recurrent and Refractory Diffuse Large b | unknown | — | 169 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05691153 | ThisCART19A for B-NHL Relapsed After Auto-CAR T | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 54 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT04287855 | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 82 | Poitiers University HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05360758 | Ibrutinib Adapted to Response in Patients With CLL | unknown | — | 80 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 0 | Dec 28, 2022 | clinicaltrials |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Kecellitics Biotech Company LtdINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02752815 | Reduced Chemotherapy in Low Risk DLBCL | unknown | Phase 4 | 290 | Ruijin HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619861 | CAR-T Cells in the Treatment of Malignant Hematological Tumors | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05415098 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | unknown | Phase 1 | 90 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03664297 | Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor | unknown | Phase 1 | 86 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT04481815 | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 240 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05577884 | Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple Myeloma | unknown | — | 30 | Seoul National University HospitalOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05479136 | 18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy(DRARCH) | unknown | Phase 3 | 30 | Nicole HillOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05596097 | Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | unknown | Phase 2 | 15 | LanZhou UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05578625 | ctDNA Methylation Sequencing for Myeloma | unknown | — | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Oct 13, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2023source: clinicaltrials